Clinicians Connect: Conversations with FDA's Chief Medical Officer
Clinicians Connect: Conversations with FDA’s Chief Medical Officer are clinically focused, interactive webinars. These webinars are held regularly on topics that are relevant and timely for health care providers.
To stay informed about future Clinicians Connect: Conversations with FDA's Chief Medical Officer, please subscribe to our mailing list.
Title: Clinicians Connect: Conversations with FDA’s Chief Medical Officer on reducing the cases of congenital syphilis and syphilis
Date: December 4, 2024, 1-2 P.M. ET
Overview: Clinicians will hear directly from the FDA, CDC, HHS, and NIH about what we can do to address the recent surge in syphilis and its impact on individuals, pregnant women and babies.
Presenters include:
- Hilary Marston, M.D., M.P.H., Chief Medical Officer, Office of the Commissioner, FDA
- Kaye Hayes, M.P.A., Deputy Assistant Secretary for Infectious Disease and Director, Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, HHS
- Susan Bersoff-Matcha, M.D., Deputy Director, Office of Women’s Health, Office of the Commissioner, FDA
- Bradley Stoner, M.D., Ph.D., Director, Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC
- Carolyn D. Deal, Ph.D., Chief, Enteric and Sexually Transmitted Infections Branch, National Institute of Allergy and Infectious Disease, NIH
Presentations:
- Presentation: Clinicians Connect Introduction
- Presentation: Role of FDA in Reducing Cases of Syphilis and Congenital Syphilis
- Presentation: NIAID Efforts to Combat Syphilis
- Presentation: Point-of-Care Tests and Doxy PEP: New Tools to Reduce Syphilis and Congenital Syphilis
Title: Clinicians Connect: Conversations with FDA's Chief Medical Officer on Overdose Prevention
Date: September 25, 2024
Overview: Clinicians hear directly from the FDA, SAMHSA, NIH and AHRQ about the latest in overdose prevention.
Presenters include:
- Hilary Marston, M.D., M.P.H., Chief Medical Officer, Office of the Commissioner, FDA
- Josh Rising, M.D., M.P.H., Senior Clinical Advisor, Office of the Commissioner, FDA
- Marta Sokolowska, Ph.D., Deputy Center Director for Substance Use and Behavioral Health, Center for Drug Evaluation and Research, FDA
- CAPT Christopher M. Jones, Pharm.D., Dr.P.H., M.P.H., Director, Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration
- Wilson M. Compton, M.D., M.P.E., Deputy Director, National Institute on Drug Abuse, National Institutes of Health
- Laura L. Sessums, J.D., M.D., Chief Physician, Office of the Director, Agency for Healthcare Research and Quality
Additional Resources
- Overdose Prevention Strategy (hhs.gov)
- Food and Drug Administration Overdose Prevention Framework | FDA
- Prescribe with Confidence | FDA
- Overdose Prevention and Response Toolkit | SAMHSA Publications and Digital Products
- Overdose Prevention and Response Toolkit (Spanish Version) | SAMHSA Publications and Digital Products
- Enhancing the National Drug Abuse Treatment Clinical Trials Network to Address Opioids | NIH HEAL Initiative
- Justice Community Opioid Innovation Network (JCOIN) | NIH HEAL Initiative
- Integrating Behavioral Health & Primary Care| AHRQ Academy
- Overdose Prevention for Health Care Providers | Overdose Prevention | CDC
Presentations
- Presentation: State of the Overdose Crisis and the Role of the Clinician
- Presentation: Addressing the Substance Use and Overdose Crisis: Putting Prevention Front and Center
- Presentation: AHRQ's Academy for Integrating Behavioral Health and Primary Care
- Presentation: CDER Perspective on Opioids and Overdose Prevention
Title: Clinicians Connect: Conversations with FDA's Chief Medical Officer: 2024 Respiratory Virus Season
Date: August 8, 2024
Overview: Clinicians hear directly from the FDA and CDC about the latest on the respiratory virus vaccine and therapeutic approval processes, medical products currently available, recommendations, and resources.
Presenters include:
- Hilary Marston, M.D., M.P.H., Chief Medical Officer, Office of the Commissioner, FDA
- Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research, FDA
- Manisha Patel, M.D., M.S., M.B.A., Chief Medical Officer, National Center for Immunization and Respiratory Diseases, CDC
- May Malik, M.A., Senior Advisor for Public Education Campaigns, HHS